Keros Therapeutics Inc (KROS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Keros Therapeutics Inc (KROS) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.25 Million) by net assets ($703.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Keros Therapeutics Inc (KROS) balance sheet quality index to measure how much of total assets are equity-financed.
Keros Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Keros Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Keros Therapeutics Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Keros Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Keros Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangzhou Shangpin Home Collection Co Ltd
SHE:300616
|
0.018x |
|
Guangzhou Jet Bio-Filtration Co Ltd
SHG:688026
|
0.038x |
|
INPAQ Technology Co Ltd
TWO:6284
|
0.036x |
|
Cion Investment Corp
NYSE:CION
|
-0.004x |
|
AB Traction
ST:TRAC-B
|
0.030x |
|
P-Duke Technology Co Ltd
TWO:8109
|
0.046x |
|
Nexpoint Real Estate Finance Inc
NYSE:NREF
|
-0.005x |
|
Taiwan Mask Corp
TW:2338
|
0.116x |
Annual Cash Flow Conversion Efficiency for Keros Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Keros Therapeutics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Keros Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $571.55 Million | $-160.87 Million | -0.281x | +24.90% |
| 2023-12-31 | $332.21 Million | $-124.51 Million | -0.375x | -48.40% |
| 2022-12-31 | $277.42 Million | $-70.06 Million | -0.253x | +1.18% |
| 2021-12-31 | $243.17 Million | $-62.15 Million | -0.256x | -81.30% |
| 2020-12-31 | $261.72 Million | $-36.89 Million | -0.141x | +95.20% |
| 2019-12-31 | $5.45 Million | $-16.00 Million | -2.935x | -631.71% |
| 2018-12-31 | $12.76 Million | $7.04 Million | 0.552x | -- |
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias… Read more